Alexion Pharmaceuticals (ALXN)
$113.27 0.76 (0.68%)
17:49 EST ALXN Stock Quote Delayed 15 Minutes
Previous Close $113.27
Market Cap 25.20B
PE Ratio 48.61
Volume (Avg. Vol.) 1.94M
Day's Range 112.47 - 114.35
52-Week Range 94.59 - 141.86
Dividend & Yield N/A (N/A)
ALXN Stock Predictions, Articles, and Alexion Pharmaceuticals News
- From InvestorPlace
- From the Web
Long-term, Alibaba could be one of the best stocks to own over the next half-decade.
These 3 big stock charts, including MCD stock, highlight S&P 500 components set up for big potential moves.
Eli Lilly, Alexion and AbbVie are just some of the top healthcare stocks to buy here, now that disappointing news has driven them to cheap prices.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Expedia, Alexion and DowDuPont are just some of the stocks to buy to overcome the marketwide lethargy that takes shape this time of year.
These 10 smart money stocks to buy have significant support from top analysts. Here's why each should help you flourish throughout the rest of the year.
With stocks trading at record levels, it can be difficult to identify the best stocks to buy now. Here are 10 picks that the experts have faith in.
Here are some stocks trading near their 52-week high levels with potential to scale higher. Compare Brokers....
Stock charts of Express Scripts, Ventas and Alexion Pharmaceuticals are shaping up as your best bets as the week nears its end.
These 7 stock picks all boast support from the Street's top analysts. If you are looking to actually make money these are the stocks I recommend snapping up now. Here I also include price targets from the Street so you can see the kind of growth potential these gems have in store.
Yes the market is tricky right now. But Goldman Sachs has a report on stocks with the potential to explode. Here I single out the stocks with a 'Strong Buy' analyst consensus and see just why they are so compelling.
Alexion stock has come under fire lately, but the company has a promising pipeline of orphan drugs that could prod others to consider a takeover.
Alexion Pharmaceuticals (ALXN) stock was up today on positive results for a recent Phase 3 clinical study for the drug ALXN1210.
The Street's best analysts of 2017 (according to TipRanks) provide us with these 10 compelling investing opportunities.
Biotech's luck is changing as the trend looks to be upward and outward for the biotech stocks. These are the five to watch.
From Analyst Ratings
J.P. Morgan analyst Cory Kasimov assigned a Buy rating to Alexion Pharmaceuticals (ALXN – Research Report) on January 14. The company’s shares closed last Monday at $113.27. According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 7.2% and a 47.5% success rate. Kasimov covers the Healthcare sector, focusing on stocks such
From Market News Video
From Market News Video
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Limoneira Co (LMNR), where a total of 223 contracts have traded so far, representing approximately 22,300 underlying shares. That amounts to about 48.6% of LMNR's average daily trading volume over the past month of 45,875 shares..
Navellier RatingsPowered by Portfolio Grader